These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35474728)

  • 21. The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis.
    Rizzo A; Santoni M; Mollica V; Ricci AD; Calabrò C; Cusmai A; Gadaleta-Caldarola G; Palmiotti G; Massari F
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
    Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
    Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
    Homicsko K; Dummer R; Hoeller C; Wolchok JD; Hodi FS; Larkin J; Ascierto PA; Atkinson V; Robert C; Postow MA; Re S; Paulucci D; Dobler D; Michielin O
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
    Rassy E; Dalban C; Colomba E; Derosa L; Alves Costa Silva C; Negrier S; Chevreau C; Gravis G; Oudard S; Laguerre B; Barthelemy P; Goupil MG; Geoffrois L; Rolland F; Thiery-Vuillemin A; Joly F; Ladoire S; Tantot F; Escudier B; Albiges L
    Clin Genitourin Cancer; 2022 Oct; 20(5):488-494. PubMed ID: 35977881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
    Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Ono Y; Tagawa T; Okamoto T; Hamatake M; Okamoto I; Mori M
    PLoS One; 2022; 17(2):e0263247. PubMed ID: 35130287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Concomitant Use of Proton Pump Inhibitors on Immunotherapy Clinical Response in Advanced Cancer Patients: Real-Life Setting.
    Cantarelli L; Gutiérrez Nicolás F; García Gil S; Morales Barrios JA; Oramas Rodriguez J; Nazco Casariego GJ
    J Immunother; 2023 Nov; ():. PubMed ID: 37937583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
    Fiala O; Buti S; Takeshita H; Okada Y; Massari F; Palacios GA; Dionese M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Quiroga MNG; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Cattrini C; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchenhorn D; Santini D; Manneh R; Bisonni R; Zakopoulou R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Sorgentoni G; Battelli N; Porta C; Bellmunt J; Santoni M
    Cancer Immunol Immunother; 2023 Nov; 72(11):3665-3682. PubMed ID: 37676282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.
    Mollica V; Santoni M; Matrana MR; Basso U; De Giorgi U; Rizzo A; Maruzzo M; Marchetti A; Rosellini M; Bleve S; Maslov D; Tawagi K; Philon E; Blake Z; Massari F
    Target Oncol; 2022 Jan; 17(1):61-68. PubMed ID: 34894318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
    Li M; Zeng C; Yao J; Ge Y; An G
    Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.
    Jun T; Ozbek U; Dharmapuri S; Hardy-Abeloos C; Zhu H; Lin JY; Personeni N; Pressiani T; Nishida N; Lee PC; Lee CJ; Hildebrand H; Nimkar N; Paul S; Fessas P; Naeem M; Bettinger D; Khan U; Saeed A; Huang YH; Kudo M; Rimassa L; Marron TU; Pinato DJ; Ang C
    Ther Adv Med Oncol; 2021; 13():17588359211010937. PubMed ID: 33995594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
    Uğraklı M; Koçak MZ; Dinç G; Genç TB; Çağlayan M; Uğraklı S; Hendem E; Er MM; Çağlayan D; Eryılmaz MK; Araz M; Geredeli Ç; Tatlı AM; Eren OÖ; Artaç M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9183-9189. PubMed ID: 37184681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
    Dar S; Merza N; Qatani A; Rahim M; Varughese T; Mohammad A; Masood F; Reza FZ; Wan S; Almas T
    Ann Med Surg (Lond); 2022 Jun; 78():103752. PubMed ID: 35600176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials.
    Hopkins AM; Badaoui S; Kichenadasse G; Karapetis CS; McKinnon RA; Rowland A; Sorich MJ
    J Thorac Oncol; 2022 Jun; 17(6):758-767. PubMed ID: 35183773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
    Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
    Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy.
    Angrish MD; Agha A; Pezo RC
    J Skin Cancer; 2021; 2021():9120162. PubMed ID: 34336290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations.
    Li J; Nickens D; Wilner K; Tan W
    Oncol Ther; 2021 Dec; 9(2):525-539. PubMed ID: 34120312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.